PharmaCyte Biotech

PharmaCyte is a biotech company developing targeted treatments for cancer and diabetes using signature live-cell encapsulation technology, Cell-in-a-Box.

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital $PMCB https://t.co/L9erppDKAD

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation $PMCB https://t.co/diLMxwfadN

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study $PMCB #Cancer #FDA #PancreaticCancer #Biotechnology https://t.co/zjphGlc5tV

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study - $PMCB #Biotechnology #Cancer https://t.co/Vd0ml2y3AG

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 $PMCB #Biotechnology #cancer #diabetes #FDA #PancreaticCancer https://t.co/ZGyfYAV1Ai

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
$PMCB #Biotechnology #Cancer #FDA https://t.co/pAgYq3l0Ln

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value $PMCB https://t.co/jk5nFFX35x

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego $PMCB #BIO2022 #biotechnology #cancer #diabetes https://t.co/f4sCRecdkU

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value $PMCB #cancer #diabetes #clinicaltrials #FDA #Biotechnology https://t.co/ui65PoFpGx

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program $PMCB #biotechnology #biotech #cancer #PancreaticCancer #diabetes #FDA #clinicaltrial #cellulartherapy https://t.co/mKJzkUnhW2

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
$PMCB #Cancer #MalignantAscites #Biotechnology #clinicalresearch https://t.co/I1LVq24zq5

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech to Attend 15th National Conference on Advanced Technologies and Treatments $PMCB #diabetes #ATTD2022 #CellEncapsulation https://t.co/94pyiinwTY

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements $PMCB #PancreaticCancer #Cancer #clinicaltrials #FDA https://t.co/siu32cvooy

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial $PMCB #PancreaticCancer #cancer #clinicaltrials #FDA https://t.co/JnnTYCHKdS

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors $PMCB https://t.co/vpojCKPvPi

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate - $PMCB #cancer #PancreaticCancer #clinicaltrials https://t.co/GvZ4CK6OJ5

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
https://t.co/AGPCjjWkYG $PMCB

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration $PMCB https://t.co/D4cbgv4QHB

[PharmaCyte Biotech @PharmaCyte]

Cross-Disciplinary Efforts in Treating Diabetes $PMCB #diabetes https://t.co/Y4p9cGxjMa via @GENbio

[PharmaCyte Biotech @PharmaCyte]

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA $PMCB #FDA #clinicaltrials #Cancer #pancreaticcancer https://t.co/5938ubYBNG